Anti-VEGF antibodies

Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C530S387300, C530S388850, C424S130100, C435S320100, C536S023530

Reexamination Certificate

active

07375193

ABSTRACT:
Humanized and variant anti-VEGF antibodies and various uses therefor are disclosed. The anti-VEGF antibodies have strong binding affinities for VEGF; inhibit VEGF-induced proliferation of endothelial cells in vitro; and inhibit tumor growth in vivo.

REFERENCES:
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 5530101 (1996-06-01), Queen et al.
patent: 5580723 (1996-12-01), Wells et al.
patent: 6037454 (2000-03-01), Jardieu et al.
patent: 6054297 (2000-04-01), Carter et al.
patent: 6884879 (2005-04-01), Baca et al.
patent: 7060269 (2006-06-01), Baca et al.
patent: 7169901 (2007-01-01), Baca et al.
patent: 2002/0032315 (2002-03-01), Baca et al.
patent: 0239400 (1987-09-01), None
patent: 0451216 (1996-01-01), None
patent: 451216 (1996-01-01), None
patent: 1 325 932 (2005-04-01), None
patent: 2188638 (1987-10-01), None
patent: 2268744 (1994-12-01), None
patent: 91/0996 (1991-01-01), None
patent: WO 91/09967 (1991-07-01), None
patent: WO 92/18619 (1992-10-01), None
patent: WO 92/22653 (1992-12-01), None
patent: WO 94/04679 (1994-03-01), None
patent: WO 94/10202 (1994-05-01), None
patent: 96/30046 (1996-10-01), None
patent: WO 98/45331 (1998-10-01), None
patent: WO 98/45332 (1998-10-01), None
Adamis et al., “Inhibition of Vascular Endothelial Growth Factor Prevents Retinal Ischemia-Associated Iris Neovascularization in a Nonhuman Primate”Arch. Ophthalmology114(1) :66-71 (1996).
Aiello et al., “Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders”New England J. of Medicine331(22) :1480-1487 (1994).
Alberts et al., “Molecular Biology of the Cell”, 3rd edition, Garland Publishing pp. 1154 (1994).
Allen et al., “Specificity of the T cell Receptor: Two Different Determinates are Generated by the Same Peptide and the IAkMolecule”J. Immunol.135(1) :368-373 (Jul. 1985).
Amit et al., “Three-Dimensional Structure of an Antigen-Antibody Complex at 2.8 A Resolution”Science233:747-753 (Aug. 1986).
Baca et al., “Antibody Humanization Using Monovalent Phage Display”Journal of Biological Chemistry272(16) :10678-10684 (1997).
Bass et al., “Hormone Phage: An Enrichment Method for Variant Proteins with Altered Binding Properties”Proteins: Structure, Function, and Genetics8(4) :309-314 (1990).
Bendig, M. M., “Humanization of Rodent Monoclonal Antibodies”Methods: A Companion to Methods in Enzymology8:83-93 (1994).
Berkman et al., “Expression of the vascular permeability factor/vascular endothelial growth factor gene in central nervous system neoplasms”J. Clin. Invest.91(1) :153-159 (1993).
Borgstrom et al., “Complete inhibition of angiogenesis and growth of microtumors by anti-vascular endothelial growth factor neutralizing antibody: novel concepts of angiostatic therapy from intravital videomicroscopy”Cancer Research56(17) :4032-4039 (Sep. 1, 1996).
Brown et al., “Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract”Cancer Research53(19) :4727-4735 (1993).
Brown et al., “Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer”Human Pathology26(1) :86-91 (1995).
Carter et al., “Humanization of an Anti-p185HER2Antibody for Human Cancer Therapy”Proc. Natl. Acad. Sci. USA89(10) :4285-4289 (May 1992).
Chang et al., “High-Level Secretion of Human Growth Hormone byEscherichia coli” Gene55:189-196 (1987).
Chen et al., “Selection and Analysis of an Optimized Anti-VEGF Antibody: Crystal Structure of an Affinity-matured Fab in Complex with Antigen”Journal of Molecular Biology293(4) :865-881 (1999).
Chisholm, “High Efficiency Gene Transfer into Mammaliam Cells”DNA Cloning 4. Mammaliam Systemspp. 1-41 (1995).
Chothia et al., “Domain Association in Immunoglobulin Molecules. The Packing of Variable Domains”Journal of Molecular Biology186(3) :651-663 (Dec. 5, 1985).
Clackson et al., “Making Antibody Fragments Using Phage Display Libraries”Nature352(15) :624-628 (Aug. 1991).
Clapp et al., “The 16-kilodalton N-terminal fragment of human prolactin is a potent inhibitor of angiogenesis”Endocrinology133(3) :1292-1299 (1993).
Coleman, P.M., “Effects of amino acid sequence changes on antibody-antigen interactions”Research in Immunology145:33-36 (1994).
Colman P.M., “Effects of amino acid sequence changes on antibody-antigen interactions”Research in Immunology145:33-36 (1994).
Cunningham et al., “Production of an Atrial Natriuretic Peptide Variant that is Specific for Type A Receptor”EMBO Journal13(11) :2508-2515 (1994).
De Vries et al., “The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor”Science255:989-991 (1992).
Dvorak et al., “Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis”American Journal of Pathology146(5) :1029-1039 (1995).
Eaton et al., “Construction and characterization of an active factor VIII variant lacking the central one-third of the molecule”Biochemistry25:8343-8347 (1986).
Eigenbrot et al., “X-Ray Structures of Fragments From Binding and Nonbinding Versions of a Humanized Anti-CD18 Antibody: Structural Indications of the Key Role of VHResidues 59 to 65”Proteins: Structure, Function, and Genetics18:49-62 (1994).
Eigenbrot et al., “X-Ray Structures of the Antigen-Binding Domains From Three Variants of Humanized Anti-p185HER2Antibody 4D5 and Comparison With Molecular Modeling”J. Mol. Biol.229:969-995 (1993).
Ferrara and Davis-Smyth, “The Biology of Vascular Endothelial Growth Factor”Endocrine Reviews18(1) :4-25 (1997).
Folkman and Shing, “Angiogenesisg”Journal of Biological Chemistry267:10931-10934 (1992).
Foote et al., “Antibody Framework Residues Affecting the Conformation of the Hypervariable Loops”J. Mol. Biol.224:487-499 (1992).
Garner, A., “Vascular Diseases”Pathobiology of Ocular Disease. A Dynamic Approach, Garner, A., Klintworth GK Eds., 2nd edition, NY:Marcel Dekker pp. 1625-1710 (1994).
Garrard et al., “Assembly and Enrichment in a Monovalent Phage Display System”Biotechnology9:1373-11377 (1997).
Garrard et al., “Fab assembly and enrichment in a monovalent phage display system”Bio/technology9:1373-1377 (1991).
Good et al., “A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin”Proc. Natl. Acad. Sci. USA87(17) :6624-6628 (1990).
Gorman et al., “Transient Production of Proteins Using an Adenovirus Transformed Cell Line”DNA Prot. Eng. Tech.2(1) :3-10 (1990).
Graham et al., “Characteristics of a Human Cell Line Transformed by DNA from Human Adenovirus Type 5”J. Gen. Virol.36:59-72 (1977).
Hawkins et al., “Selection of Phage Antibodies by Binding Affinity Mimicking Affinity Maturation”J. Mol. Biol.226:889-896 (1992).
Horak et al., “Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer”Lancet340(8828) :1120-1124 (1992).
Ibragimova and Wade, “Stability of the β-sheet of the WW Domain: A Molecular Dynamics Simulation Study”Biophysical Journal77:2191-2198 (Oct. 1999).
Kabat et al.Sequences of Proteins of Immunological Interest, U.S. Dept. of Health and Human Services, NIH, 5th edition vol. 1:103-108, 324-331 (1991).
Karlsson et al., “Kinetic analysis of monoclonal antibody-antigen interactions with a new biosensor based analytical system”J. Immun. Methods145:229-240 (1991).
Karlsson et al., “Kinetic and Concentration Analysis Using BIA Technology”Methods

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Anti-VEGF antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Anti-VEGF antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-VEGF antibodies will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-2747181

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.